Profile data is unavailable for this security.
About the company
PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
- Revenue in USD (TTM)198.51m
- Net income in USD-63.78m
- Incorporated1986
- Employees105.00
- LocationPDL BioPharma Inc932 Southwood BlvdINCLINE VILLAGE 89451United StatesUSA
- Phone+1 (775) 832-8500
- Fax+1 (775) 832-8501
- Websitehttp://www.pdl.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merus NV | 32.80m | -24.74m | 361.67m | 98.00 | -- | 3.71 | -- | 11.03 | -1.08 | -1.08 | 1.43 | 4.17 | 0.1309 | -- | 5.10 | 334,730.70 | -9.87 | -41.80 | -11.37 | -49.24 | -- | -- | -75.40 | -299.35 | -- | -- | 0.0112 | -- | 43.50 | 123.97 | 62.53 | -- | 79.62 | -- |
| Collegium Pharmaceutical Inc | 291.18m | -30.18m | 361.91m | 266.00 | -- | 4.19 | 6.63 | 1.24 | -0.9114 | -0.9114 | 8.81 | 2.59 | 0.5879 | 20.64 | 3.85 | 1,094,662.00 | -6.09 | -46.02 | -10.94 | -66.89 | 41.02 | -- | -10.36 | -81.57 | 1.19 | -1.37 | 0.1175 | -- | 884.73 | -- | 47.74 | -- | 159.74 | -- |
| ProQR Therapeutics NV | 6.37m | -45.32m | 362.46m | 119.00 | -- | 3.98 | -- | 56.88 | -1.24 | -1.24 | 0.1782 | 2.11 | 0.0789 | -- | -- | 53,549.58 | -56.45 | -39.05 | -63.70 | -42.22 | -- | -- | -715.27 | -1,209.81 | -- | -- | 0.1131 | -- | 285.35 | 118.38 | 15.45 | -- | 17.89 | -- |
| Eloxx Pharmaceuticals Inc | 0.00 | -50.51m | 365.97m | 29.00 | -- | 9.60 | -- | -- | -1.47 | -1.47 | 0.00 | 0.9579 | 0.00 | -- | -- | 0.00 | -132.84 | -- | -163.02 | -- | -- | -- | -- | -- | -- | -- | 0.2948 | -- | -- | -- | -99.78 | -- | -- | -- |
| resTORbio, Inc. | 0.00 | -38.82m | 371.37m | 21.00 | -- | 2.61 | -- | -- | -1.37 | -1.37 | 0.00 | 3.98 | 0.00 | -- | -- | 0.00 | -27.50 | -- | -28.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.36 | -- | -- | -- |
| Gritstone Oncology Inc | 2.53m | -69.41m | 372.19m | 127.00 | -- | 2.29 | -- | 146.88 | -2.40 | -2.40 | 0.0875 | 4.56 | -- | -- | -- | 22,424.78 | -- | -- | -- | -- | -- | -- | -2,739.07 | -- | -- | -- | 0.00 | -- | -- | -- | -56.55 | -- | -- | -- |
| NextCure Inc | -100.00bn | -100.00bn | 374.79m | 44.00 | -- | -- | -- | -- | -- | -- | -- | 4.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0437 | -- | -- | -- | -47.39 | -- | -- | -- |
| Arcus Biosciences Inc | 8.85m | -54.31m | 376.32m | 108.00 | -- | 1.70 | -- | 42.51 | -2.21 | -2.21 | 0.2551 | 4.98 | 0.0314 | -- | 327.89 | 81,972.22 | -19.26 | -- | -20.47 | -- | -- | -- | -613.46 | -- | -- | -- | 0.00 | -- | 491.15 | -- | 6.57 | -- | -- | -- |
| BioCryst Pharmaceuticals, Inc. | 22.56m | -106.53m | 381.68m | 100.00 | -- | 16.95 | -- | 16.92 | -0.999 | -0.999 | 0.2128 | 0.2041 | 0.1516 | 5.99 | 4.22 | 225,640.00 | -71.57 | -49.65 | -136.54 | -92.91 | 91.95 | 94.86 | -472.12 | -231.53 | 1.76 | -17.36 | 0.7861 | -- | -18.00 | 3.57 | -53.92 | -- | 64.92 | -- |
| PDL BioPharma Inc | 198.51m | -63.78m | 382.48m | 105.00 | -- | 0.5643 | -- | 1.93 | -0.4189 | -0.4189 | 1.42 | 5.62 | 0.1962 | 3.43 | 10.34 | 1,890,524.00 | -6.31 | 14.68 | -6.62 | 17.28 | 74.46 | -- | -32.16 | 39.36 | 10.67 | 24.51 | 0.1543 | 27.81 | -38.10 | -15.37 | -161.78 | -- | -36.70 | -- |
| Stealth BioTherapeutics Corp | -100.00bn | -100.00bn | 385.33m | 57.00 | -- | 11.17 | -- | -- | -- | -- | -- | 0.9849 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3298 | -- | -- | -- | -16.65 | -- | -- | -- |
| Prothena Corporation PLC | 914.00k | -127.77m | 389.48m | 59.00 | -- | 1.25 | -- | 426.12 | -3.20 | -3.20 | 0.0229 | 7.83 | 0.0017 | -- | -- | 15,491.53 | -23.97 | -28.05 | -25.16 | -29.92 | -- | -- | -13,978.88 | -679.54 | -- | -- | 0.0152 | -- | -96.53 | 7.15 | -1.31 | -- | 25.67 | -- |
| Beyondspring Inc | 0.00 | -48.51m | 391.12m | 52.00 | -- | -- | -- | -- | -2.12 | -2.12 | 0.00 | -0.6401 | 0.00 | -- | -- | 0.00 | -322.77 | -- | -1,266.41 | -- | -- | -- | -- | -- | -- | -100.02 | -- | -- | -- | -- | 40.21 | -- | -- | -- |
| Marker Therapeutics Inc | 205.99k | -147.96m | 396.17m | 11.00 | -- | 6.66 | -- | 1,923.25 | -4.41 | -4.41 | 0.0108 | 1.31 | 0.0061 | -- | -- | 18,726.36 | -439.54 | -443.10 | -469.72 | -1,775.94 | -- | -- | -71,827.72 | -109,881.50 | -- | -- | 0.00 | -- | -- | -- | -1,247.26 | -- | -- | -- |
| AC Immune SA | 81.82m | 24.55m | 397.94m | 104.00 | 18.37 | 1.62 | 15.47 | 4.86 | 0.3206 | 0.3206 | 1.27 | 3.63 | 0.3732 | -- | 82.38 | 786,702.70 | 11.20 | -10.63 | 13.33 | -11.56 | -- | -- | 30.01 | -44.53 | -- | 17.35 | 0.1696 | -- | -64.48 | -3.59 | -92.92 | -- | 49.48 | -- |
Data as of Jul 17 2019. Currency figures normalised to PDL BioPharma Inc's reporting currency: US Dollar USD
58.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 31 Mar 2019 | 12.04m | 10.07% |
| BlackRock Fund Advisorsas of 31 Mar 2019 | 11.35m | 9.49% |
| The Vanguard Group, Inc.as of 31 Mar 2019 | 10.49m | 8.77% |
| Renaissance Technologies LLCas of 31 Mar 2019 | 9.63m | 8.05% |
| SSgA Funds Management, Inc.as of 31 Mar 2019 | 6.37m | 5.32% |
| Connor, Clark & Lunn Investment Management Ltd.as of 31 Mar 2019 | 4.99m | 4.17% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2019 | 4.69m | 3.92% |
| Brandes Investment Partners LPas of 31 Mar 2019 | 4.35m | 3.63% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2019 | 3.47m | 2.90% |
| RBC Capital Markets LLC (Investment Management)as of 31 Mar 2019 | 3.09m | 2.59% |
More ▼
Data from 31 Mar 2019 - 30 Jun 2019Source: FactSet Research Systems Inc.
